Effects of 'non-calcaemic' vitamin D analogues on 24-hydroxylase expression in MG-63 osteoblast-like cells

Nephron

Volumn 94, Issue 4, 2003, Pages

  Schroeder, Neil J ^a   Burrin, Jacky M ^a   Noonan, Kate ^a   Makin, Hugh L J ^a   Cunningham, John ^a,b  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

1,25 Dihydroxyvitamin D3; 24 Hydroxylase; MG 63; mRNA; Vitamin D analogues

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 19 NOR 1,25 DIHYDROXYVITAMIN D2; 22 OXACALCITROL; CALCITRIOL; CALCITRIOL DERIVATIVE; ENZYME; MESSENGER RNA; PARICALCITOL; STEROID 24 HYDROXYLASE; UNCLASSIFIED DRUG; VITAMIN; VITAMIN D; VITAMIN D RECEPTOR; 22 OXACALCITRIOL; CALCITRIOL RECEPTOR; CYTOCHROME P450; DIHYDROTACHYSTEROL; DRUG DERIVATIVE; ERGOCALCIFEROL; MIXED FUNCTION OXIDASE; STEROID MONOOXYGENASE; VITAMIN D 24 HYDROXYLASE; VITAMIN D 24-HYDROXYLASE;

ARTICLE; BINDING AFFINITY; CALCIUM BLOOD LEVEL; CELL LINE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; HUMAN CELL; METABOLISM; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TARGET CELL; THYMUS; ANIMAL; BIOSYNTHESIS; CATTLE; CHEMISTRY; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HYDROXYLATION; PROTEIN BINDING;

ANIMALS; CALCITRIOL; CATTLE; CELL LINE; CYTOCHROME P-450 ENZYME SYSTEM; DIHYDROTACHYSTEROL; ERGOCALCIFEROLS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYDROXYLATION; MIXED FUNCTION OXYGENASES; OSTEOBLASTS; PROTEIN BINDING; RECEPTORS, CALCITRIOL; STEROID HYDROXYLASES; THYMUS GLAND;

EID: 0346307676     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072519     Document Type: Article

References (43)

1. Jones G, Strugnell SA, DeLuca HF: Current understanding of the molecular actions of vitamin D. Physiol Rev 1998;78:1193-1231.
2. 3. Endocrinology 1997;138:2233-2240.
3. 3-hydroxylases. Steroids 2001;66:399-408.
4. 3 through C-24 oxidation pathway. Biochemistry 1989;28:1763-1769.
5. 3 to calcitroic acid. Evidence for a pathway in kidney and bone involving 24-oxidation. Biochem J 1989;262:173-180.
6. Akiyoshi-Shibata M, Sakaki T, Ohyama Y, Noshiro M, Okuda K, Yabusaki Y: Further oxidation of hydroxycalcidiol by calcidiol 24-hy-droxylase. A study with the mature enzyme expressed in Escherichia coli. Eur J Biochem 1994;224:335-343.
7. 3-24-hydroxylase, a multicatalytic enzyme. Biochemistry 1996;35:8465-8472.
8. 3 to calcitroic acid. Eur J Biochem 1999;262:43-48.
9. Demers C, Lemay J, Hendy GN, Gascon-Barre M: Comparative in vivo expression of the calcitriol-24-hydroxylase gene in kidney and intestine. J Mol Endocrinol 1997;18:37-48.
10. 2. J Steroid Biochem Mol Biol 1985;23:223-229.
11. 3 formed in the isolated perfused rat kidney: A model for the study of side-chain metabolism of vitamin D. Biochemistry 1988;25:5328-5336.
12. Qaw F, Calverley MJ, Schroeder NJ, Trafford DJ, Makin HL, Jones G: In vivo metabolism of the vitamin D analog, dihydrotachysterol. Evidence for formation of 1alpha,25- and 1beta,25-dihydroxy-dihydrotachysterol metabolites and studies of their biological activity. J Biol Chem 1993;268:282-292.
13. Akizawa T, Suzuki M, Akiba T, Nishizawa Y, Kurokawa K: Clinical effects of maxacalcitol on secondary hyperparathyroidism of uremic patients. Am J Kidney Dis 2001;38(suppl 1):S147-S151.
14. Sprague SM, Lerma E, McCormmick D, Abraham M, Batlle D: Suppression of parathyroid hormone secretion in hemodialysis patients: Comparison of paricalcitol with calcitriol. Am J Kidney Dis 2001;38(suppl 5):S51-S56.
15. 3 concentrations. J Clin Endocrinol Metab 1994;78: 1481-1487.
16. 2. Nephrol Dial Transplant 2000;12:1943-1949.
17. McIntyre CW, Schroeder NJ, Burrin JM, Cunningham J: Effects of new analogues of vitamin D on bone cells: Implications for treatment of uremic bone disease. Kidney Int 1999;55:500-511.
18. 3 and its analogs. Life Sci 1998;62:453-459.
19. 3-analogs on osteoblast-like cells and on in vitro bone resorption. J Steroid Biochem Mol Biol 1995;55:337-346.
20. Mahonen A, Jaaskelainen T, Maenpaa PH: A novel vitamin D analog with two double bonds in its side chain. A potent inducer of osteoblastic cell differentiation. Biochem Pharmacol 1996;51:887-892.
21. 2 on inducing differentiation and markers of bone formation in MG-63 cells. J Am Soc Nephrol 2001;12:1468-1474.
22. Lajeunesse D, Kiebzak GM, Frondoza C, Sacktor B: Regulation of osteocalcin secretion by human primary bone cells and by the human osteosarcoma cell line MG-63. Bone Miner 1991;14:237-250.
23. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S: Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 1999;25:255-259.
24. Blair HC, Sidonio RF, Friedberg RC, Khan NN, Dong SS: Proteinase expression during differentiation of human osteoclasts in vitro. J Cell Biochem 2000;78:627-637.
25. 3. Endocrinology 1999;140:381-391.
26. 3. J Invest Dermatol 1996;106:637-641.
27. Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, Von Hoff DD, Roninson IB: Quantitative analysis of multidrug gene expression in human tumours by PCR. Proc Natl Acad Sci USA 1990;98:7160-7164.
28. Salomon RN, Underwood R, Doyle MV, Wang A, Libby P: Increased apolipoprotein E and cfms gene expression without elevated interleukin 1 or 6 mRNA levels indicates selective activation of macrophage functions in advanced human atheroma. Proc Natl Acad Sci USA 1992;89:7706-7710.
29. Makin HLJ, Jones G, Calverley MJ: Analgin of vitamin D, its metabolites and analogues; in Makin HLJ, Gower DB, Kirk DN (eds): Modern Analysis of Steroids. London, Chapman & Hall, 1995, pp 562-620.
30. Masuda S, Byford V, Kremer R., Makin HLJ, Kubodera N, Nishii Y, Okazaki A, Okano T, Kobayashi T, Jones G: In vitro metabolism of the vitamin D analog, 22-oxacalcitriol, using cultured osteosarcoma, hepatoma, and keratinocyte cell lines. J Biol Chem 1996;271:8700-8708.
31. Shankar VN, Byford V, Prosser DE, Schroeder NJ, Makin HL, Wiesinger H, Neef G, Steinmeyer A, Jones G: Metabolism of a 20-methyl substituted series of vitamin D analogs by cultured human cells: Apparent reduction of 23-hydroxylation of the side chain by the 20-methyl group. Biochem Pharmacol 2001;61:893-902.
32. 2. Arch Biochem Biophys 1999;368:319-328.
33. Chen KS, DeLuca HF: Cloning of the human 1 alpha,25-dihydroxyvitamin D-3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements. Biochim Biophys Acta 1995;1263:1-9.
34. 3 24-hydroxylase gene. J Biol Chem 1994;269:10545-10550.
35. Kerry DM, Dwivedi PP, Hahn CN, Morris HA, Omdahl JL, May BK: Transcriptional synergism between vitamin D-responsive elements in the rat 25-hydroxyvitamin D3 24-hydroxylase (CYP24) promoter. J Biol Chem 1996;271:29715-29721.
36. St-Arnaud R, Arabian A, Travers R, Barletta F, Raval-Pandya M, Chapin K, Depovere J, Mathieu C, Christakos S, Demay MB, Glorieux FH: Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylaseablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology 2000;141: 2658-2666.
37. Dilworth FJ, Williams GR, Kissmeyer AM, Nielsen JL, Binderup E, Calverley MJ, Makin HL, Jones G: The vitamin D analog, KH1060, is rapidly degraded both in vivo and in vitro via several pathways: Principal metabolites generated retain significant biological activity. Endocrinology 1997;138:5485-5496.
38. Siu-Caldera ML, Sekimoto H, Peleg S, Nguyen C, Kissmeyer A-M, Binderup L, Weiskopf A, Vouros P, Uskokovic MR, Reddy GS: Enhanced biological activity of 1alpha,25-dihydroxy-20-epi-vitamin D3, the C-20 epimer of 1alpha,25- dihydroxyvitamin D3, is in part due to its metabolism into stable intermediary metabolites with significant biological activity. J Steroid Biochem Mol Biol 1999;71:111-121.
39. Kubodera NK, Okano T, Nakagawa K, Ozono K, Mikami K: Biological activities of 19-nor-1alpha,25-dihydroxyvitamin D3 analogs singly dehydroxylated at the C-1 or C-3 position of the A-ring. Curr Pharm Des 2000;6:791-801.
40. Peleg S, Sastry M, Collins ED, Bishop JE, Norman AW: Distinct conformational changes induced by 20-epi analogues of 1alpha, 25-dihydroxyvitamin D3 are associated with enhanced activation of the vitamin D receptor. J Biol Chem 1995;270:10551-10558.
41. Sunn KL, Cock TA, Crofts LA, Eisman JA, Gardiner EM: Novel n-terminal variant of human vdr. Mol Endocrinol 2001;9:1599-1609.
42. Messerlian S, Gao X, and St-Arnaud R: The 3-epi- and 24-oxo-derivatives of 1alpha,25-dihydroxyvitamin D(3) stimulate transcription through the vitamin D receptor. J Steroid Biochem Mol Biol 2000;72:29-34.
43. Zimmerman DR, Reinhardt TA, Kremer R, Beitz DC, Reddy GS, Horst RL: Calcitroic acid is a major catabolic metabolite in the metabolism of 1alpha-dihydroxyvitamin D(2). Arch Biochem Biophys 2001;392:14-22.